PRIMARY STUDY

Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the VESIsorb® Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS)

Key Findings:  This study measured the oral bioavailability of β-Caryophyllene (BCP) in a self-emulsifying drug delivery system (SEDDS) when given to healthy subjects. It was deemed safe and well-tolerated, and the SEDDS system effectively increased the bioavailability BCP.

Type of Study:  Double Blind Clinical Trial

Study Sample Size:  24

Study Result:  Positive

Study Location(s):  Germany, Switzerland, United States

Year of Pub:  2022


Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC)

Phytocannabinoid Source:  Not Applicable

Terpenes Studied:  ß-Caryophyllene

Receptors Studied:  CB1, CB2, PPAR - Alpha, PPAR - Gamma, PPARs

Ligands Studied:  Serotonin

Dosage: BCP (100 mg single dose)

Route of Administration:  Oral (Ingestion)



Link to study